News Release

IND Approved In China

Date: Jan 30, 2002

TSX Venture Exchange Trading Symbol: WXI
http://www.wextech.ca
E-mail: wex@wextech.ca

International Wex Technologies Inc., (the "Company") is pleased to announce that the Centre for Drug Evaluation (CDE) of the State Drug Administration (SDA) in China has formally approved the Investigational Drug Administration (IND) application submitted in1999 for its TTX pharmaceutical product.

This is a key milestone for the Company and reflects that the CDE accepts all of the pre-clinical research completed in China, including CMC (Chemistry, Manufacturing & Control), toxicology, pharmacology, etc. To the Company's knowledge this is the first time within the new rules and regulations under the SDA that an IND submission for a Class 1 drug has been accepted.

The Company must now provide the sites for clinical trials and its protocol. This must be accepted by the ethics committee. The ethics committee must be compiled of at least 5 individuals from various areas i.e., pharmacy, legal, etc. and it is recommended to include both sexes. When the appropriate acceptance forms are properly reviewed and signed by the ethics committee they will have to be sent to the SDA.

In the area of neuro-bioscience, the Company is focusing on the fields of pain management, drug addiction treatment and anaesthesia. The Company is developing products that contain a sodium channel blocking compound and derivatives extracted from natural organic substance using its proprietary manufacturing technology.

For additional information on our products, view the Company website at http://www.wextech.ca or call Howard Milne, V.P. Corporate Communications, at 604-683-8880 or 1-800-722-7549.

Per: Donna Shum, Corporate Secretary

The Canadian Venture Stock Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this News Release.